JP2005530866A - 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法 - Google Patents

有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法 Download PDF

Info

Publication number
JP2005530866A
JP2005530866A JP2004503512A JP2004503512A JP2005530866A JP 2005530866 A JP2005530866 A JP 2005530866A JP 2004503512 A JP2004503512 A JP 2004503512A JP 2004503512 A JP2004503512 A JP 2004503512A JP 2005530866 A JP2005530866 A JP 2005530866A
Authority
JP
Japan
Prior art keywords
cyclodextrin
complex
organic
solvent
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004503512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530866A5 (https=
Inventor
雲清 劉
西瑛 劉
▲韋▼ 劉
▲丹▼ 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005530866A publication Critical patent/JP2005530866A/ja
Publication of JP2005530866A5 publication Critical patent/JP2005530866A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2004503512A 2002-05-10 2003-05-09 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法 Pending JP2005530866A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB021167664A CN1232539C (zh) 2002-05-10 2002-05-10 有机药物与倍他环糊精衍生物的配合物及其制备方法
PCT/CN2003/000337 WO2003095498A1 (en) 2002-05-10 2003-05-09 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process

Publications (2)

Publication Number Publication Date
JP2005530866A true JP2005530866A (ja) 2005-10-13
JP2005530866A5 JP2005530866A5 (https=) 2006-05-11

Family

ID=4744229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004503512A Pending JP2005530866A (ja) 2002-05-10 2003-05-09 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法

Country Status (8)

Country Link
US (1) US20050215520A1 (https=)
EP (1) EP1514877A4 (https=)
JP (1) JP2005530866A (https=)
KR (1) KR20050013548A (https=)
CN (2) CN1232539C (https=)
AU (1) AU2003242083A1 (https=)
CA (1) CA2484835A1 (https=)
WO (1) WO2003095498A1 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008273899A (ja) * 2007-05-02 2008-11-13 Toa Yakuhin Kk 経鼻吸収用睡眠導入剤
JP2009531343A (ja) * 2006-03-29 2009-09-03 バイオスフィングス アクチエンゲゼルシャフト キサンテート類とシクロデキストリン類の会合物およびそれらの使用
JP2013525301A (ja) * 2010-04-16 2013-06-20 カンバーランド ファーマシューティカルズ，インコーポレーテッド 安定化スタチン製剤
JP2013537170A (ja) * 2010-09-21 2013-09-30 グァンチョウ セルプロテック ファーマシューティカル リミテッド ５α−アンドロスタン−３β，５，６β−トリオール注射剤及びその調製方法
JP2014516052A (ja) * 2011-05-27 2014-07-07 コリア フード リサーチ インスティチュート ヒスタミン受容体活性阻害用の薬剤学的組成物、及び、睡眠障害、不安またはうつ病の予防または改善用食品組成物
JP2017509697A (ja) * 2014-02-27 2017-04-06 ビー‐オーガニック フィルムス コーポレイションＢ−Ｏｒｇａｎｉｃ Ｆｉｌｍｓ Ｃｏｒｐ． 一重らせんｖ構造を有する官能化デンプン中に含まれる生物活性剤
JP2019504042A (ja) * 2015-12-21 2019-02-14 広州市香雪製薬股▲ふん▼有限公司Ｇｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 経口製剤およびその製造方法
JP2019506377A (ja) * 2015-12-21 2019-03-07 広州市香雪製薬股▲ふん▼有限公司Ｇｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 薬物包接化合物、その製剤、およびそのための製造方法
JP2019534864A (ja) * 2016-09-23 2019-12-05 アンコール ビジョン， インコーポレイテッド リポ酸コリンエステル組成物及び医薬的に適切な製剤中で安定化させる方法
JP2020033285A (ja) * 2018-08-29 2020-03-05 日本食品化工株式会社 マクロライド化合物の苦味抑制剤
JP2020518608A (ja) * 2017-05-03 2020-06-25 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
WO2021049825A1 (ko) * 2019-09-09 2021-03-18 주식회사태준제약 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
JP2021534233A (ja) * 2018-08-07 2021-12-09 江▲蘇▼▲領▼航生物科技有限公司 ブスルファン組成物及びその調製方法と使用
JP2022501432A (ja) * 2018-09-17 2022-01-06 キャンゲット バイオテクファーマ， エルエルシー ヒト疾患の治療のためのｆｌ１１８プラットフォーム位置７および９由来の類似体の組成、合成、処方および適用の問題
WO2022045212A1 (ja) * 2020-08-27 2022-03-03 協和ファーマケミカル株式会社 トリスルフィド化合物及びその包接体

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275594A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2006115494A1 (en) * 2005-04-26 2006-11-02 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
EP1671653B1 (en) * 2004-12-17 2007-08-01 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
US8580954B2 (en) * 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
KR101304343B1 (ko) 2006-04-06 2013-09-11 한미사이언스 주식회사 Ｐｄｅ-5 억제제의 경구용 속용제형
DE102006041637B4 (de) * 2006-09-05 2010-11-25 Seereal Technologies S.A. Wiedergabevorrichtung und Verfahren zum Nachführen eines Betrachterfensters
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
KR100798932B1 (ko) * 2006-09-19 2008-01-29 광주과학기술원 수용해도가 개선된 파크리탁셀을 함유하는 포접복합체 및그 제조방법
CN101134108B (zh) * 2006-10-27 2010-05-12 重庆华邦制药股份有限公司 地奈德环糊精包合物及其制备方法
US20100055172A1 (en) * 2006-11-03 2010-03-04 Choi Yong Han Encapsulated soy extracts and process for preparing same
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EP2307056B1 (en) * 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Stabilized aqueous formulation containing paracetamol
WO2010070617A1 (en) 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
CA2763365C (en) 2009-05-29 2016-09-13 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
PT2277546E (pt) * 2009-07-23 2015-09-25 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A Formulação de paracetamol injectável estável pronta a utilizar
CN101928356B (zh) * 2010-08-12 2013-06-05 中南民族大学 双-[6-氧-(2-间羧基苯磺酰基-丁二酸1,4单酯-4)]-β-环糊精及制备方法和用途
CN101985481B (zh) * 2010-08-12 2012-10-24 中南民族大学 双[-6-氧-(-3-间硝基苯磺酰基-丁二酸-1,4-单酯-4-)-]-β-环糊精及制备方法和用途
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
CN102181078A (zh) * 2010-12-29 2011-09-14 天津科技大学 一种提高沃氏氧化物生物催化效率的包合物制备方法
AU2011200289B2 (en) * 2011-01-24 2016-10-13 Ioulia Tseti Stable ready to use injectable paracetamol formulation
CN102266568A (zh) * 2011-08-01 2011-12-07 扬州大学 一种紫杉醇的羟丙基环糊精包合物的制备方法
CN102670490A (zh) * 2012-05-10 2012-09-19 南京特丰药业股份有限公司 一种伊曲康唑口服溶液及其制备方法
CN103110636B (zh) * 2013-02-19 2014-07-23 青岛正大海尔制药有限公司 酚咖滴丸及其制备方法
CN103142545B (zh) * 2013-03-21 2014-05-21 青岛正大海尔制药有限公司 一种依托泊苷肠溶胶囊
CN103142499B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种依托泊苷颗粒
ITRM20130268A1 (it) * 2013-05-06 2014-11-07 Medivis S R L Formulazioni oftalmiche acquose a base di azitromicina.
TWI568365B (zh) * 2014-07-22 2017-02-01 蘇廷弘 抑菌複合物及其製造方法
CN105566316A (zh) * 2014-10-17 2016-05-11 刘力 二苯并喹嗪类化合物实体及其用途
CN107080736A (zh) * 2017-03-22 2017-08-22 山东信谊制药有限公司 一种劳拉西泮片的制备方法
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
ES2914305T3 (es) 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma
CN108078989B (zh) * 2018-02-23 2021-01-01 中国中医科学院中药研究所 一种治疗疟疾的药物组合物
CN110237028A (zh) * 2019-06-20 2019-09-17 南京知和医药科技有限公司 一种硫辛酸注射液及制备工艺
WO2021191803A1 (en) * 2020-03-23 2021-09-30 Czap Research And Development, Llc Oral terpene cyclodextrin inclusion complex vehicles
CN114917365B (zh) * 2022-06-09 2023-12-08 上海彤颜实业有限公司 Wgx50环糊精包合物、制备方法、溶解度及环糊精包裹率测定方法
CN115399332B (zh) * 2022-08-31 2024-01-26 河北科技大学 噁线酚包合物、其制备方法和含有该包合物的组合物
CN117462451B (zh) * 2023-12-28 2024-04-02 拉芳家化股份有限公司 一种含抗真菌剂的组合物以及制备与应用
CN121177516A (zh) * 2025-11-12 2025-12-23 临沂市人民医院 一种环糊精-枸橼酸他莫昔芬包合物载药系统及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004888A1 (en) * 1990-09-20 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers
JPH05178765A (ja) * 1991-06-21 1993-07-20 Takeda Chem Ind Ltd 溶解性が向上した難水溶性薬物組成物
JPH07165801A (ja) * 1991-02-25 1995-06-27 F Hoffmann La Roche Ag 包接錯体及びその製造法
WO1996040262A2 (en) * 1995-06-07 1996-12-19 The Procter & Gamble Company Process for preparing encapsulated water soluble beta-carotene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT37857A (en) * 1983-03-30 1986-03-28 Sandoz Ag Insectide compositions containing cyclodextrin inclusion complex as active substance and process for preparing the active substances
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
CH685391A5 (fr) * 1992-07-24 1995-06-30 Achille Benakis Combinaison pharmaceutique renfermant un complexe de l'artemisinine et de ses dérivés avec des cyclodextrines et préparation de cette combinaison.
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004888A1 (en) * 1990-09-20 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers
JPH07165801A (ja) * 1991-02-25 1995-06-27 F Hoffmann La Roche Ag 包接錯体及びその製造法
JPH05178765A (ja) * 1991-06-21 1993-07-20 Takeda Chem Ind Ltd 溶解性が向上した難水溶性薬物組成物
WO1996040262A2 (en) * 1995-06-07 1996-12-19 The Procter & Gamble Company Process for preparing encapsulated water soluble beta-carotene

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531343A (ja) * 2006-03-29 2009-09-03 バイオスフィングス アクチエンゲゼルシャフト キサンテート類とシクロデキストリン類の会合物およびそれらの使用
JP2008273899A (ja) * 2007-05-02 2008-11-13 Toa Yakuhin Kk 経鼻吸収用睡眠導入剤
JP2013525301A (ja) * 2010-04-16 2013-06-20 カンバーランド ファーマシューティカルズ，インコーポレーテッド 安定化スタチン製剤
US8933115B2 (en) 2010-04-16 2015-01-13 Cumberland Pharmaceuticals Inc. Stabilized statin formulations
US9820966B2 (en) 2010-04-16 2017-11-21 Cumberland Pharmaceuticals Stabilized statin formulations
JP2013537170A (ja) * 2010-09-21 2013-09-30 グァンチョウ セルプロテック ファーマシューティカル リミテッド ５α−アンドロスタン−３β，５，６β−トリオール注射剤及びその調製方法
JP2014516052A (ja) * 2011-05-27 2014-07-07 コリア フード リサーチ インスティチュート ヒスタミン受容体活性阻害用の薬剤学的組成物、及び、睡眠障害、不安またはうつ病の予防または改善用食品組成物
JP2017509697A (ja) * 2014-02-27 2017-04-06 ビー‐オーガニック フィルムス コーポレイションＢ−Ｏｒｇａｎｉｃ Ｆｉｌｍｓ Ｃｏｒｐ． 一重らせんｖ構造を有する官能化デンプン中に含まれる生物活性剤
US12109217B2 (en) 2014-02-27 2024-10-08 B-Organic Films Corp. Bioactive agents included in functionalized starch having a single helix V-structure
US11007141B2 (en) 2015-12-21 2021-05-18 Guangzhou Xiangxue Pharmaceutical Co., Ltd. Oral preparation and preparation method thereof
US11071737B2 (en) 2015-12-21 2021-07-27 Guangzhou Xiangxue Pharmaceutical Co., Ltd. Drug inclusion complex, preparation thereof, and preparation method thereof
JP2019504042A (ja) * 2015-12-21 2019-02-14 広州市香雪製薬股▲ふん▼有限公司Ｇｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 経口製剤およびその製造方法
JP2019506377A (ja) * 2015-12-21 2019-03-07 広州市香雪製薬股▲ふん▼有限公司Ｇｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 薬物包接化合物、その製剤、およびそのための製造方法
JP2019534864A (ja) * 2016-09-23 2019-12-05 アンコール ビジョン， インコーポレイテッド リポ酸コリンエステル組成物及び医薬的に適切な製剤中で安定化させる方法
JP7091318B2 (ja) 2016-09-23 2022-06-27 ノバルティス アーゲー リポ酸コリンエステル組成物及び医薬的に適切な製剤中で安定化させる方法
JP7204670B2 (ja) 2017-05-03 2023-01-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
JP7597778B2 (ja) 2017-05-03 2024-12-10 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
JP2023026562A (ja) * 2017-05-03 2023-02-24 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
JP2020518608A (ja) * 2017-05-03 2020-06-25 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
JP7185358B2 (ja) 2018-08-07 2022-12-07 江▲蘇▼▲領▼航生物科技有限公司 ブスルファン組成物及びその調製方法と使用
JP2021534233A (ja) * 2018-08-07 2021-12-09 江▲蘇▼▲領▼航生物科技有限公司 ブスルファン組成物及びその調製方法と使用
JP2020033285A (ja) * 2018-08-29 2020-03-05 日本食品化工株式会社 マクロライド化合物の苦味抑制剤
JP2022501432A (ja) * 2018-09-17 2022-01-06 キャンゲット バイオテクファーマ， エルエルシー ヒト疾患の治療のためのｆｌ１１８プラットフォーム位置７および９由来の類似体の組成、合成、処方および適用の問題
WO2021049825A1 (ko) * 2019-09-09 2021-03-18 주식회사태준제약 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
US12576126B2 (en) 2019-09-09 2026-03-17 Taejoon Pharmaceutical Co., Ltd. Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
JPWO2022045212A1 (https=) * 2020-08-27 2022-03-03
WO2022045212A1 (ja) * 2020-08-27 2022-03-03 協和ファーマケミカル株式会社 トリスルフィド化合物及びその包接体
JP7684315B2 (ja) 2020-08-27 2025-05-27 協和ファーマケミカル株式会社 トリスルフィド化合物及びその包接体
US12552764B2 (en) 2020-08-27 2026-02-17 Kyowa Pharma Chemical Co., Ltd. Trisulfide compound and clathrate thereof

Also Published As

Publication number Publication date
CN1232539C (zh) 2005-12-21
CN1379047A (zh) 2002-11-13
WO2003095498A1 (en) 2003-11-20
EP1514877A1 (en) 2005-03-16
CN1653089A (zh) 2005-08-10
EP1514877A4 (en) 2005-12-28
AU2003242083A1 (en) 2003-11-11
KR20050013548A (ko) 2005-02-04
CA2484835A1 (en) 2003-11-20
CN100467494C (zh) 2009-03-11
US20050215520A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
JP2005530866A (ja) 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
Conceicao et al. Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art
EP2019664B1 (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
SK287487B6 (sk) Lyofilizovaná kompozícia a rekonštituovaná lyofilizovaná kompozícia
CN100518831C (zh) 固体纳米药物及其制备方法
KR101731155B1 (ko) 안정화된 보리코나졸 조성물
EP3485887B1 (en) Injectable pharmaceutical composition of tecovirimat and preparation method thereof
WO2008148080A2 (en) Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
WO2001041757A1 (en) Cyclodextrin-containing pharmaceutical composition
EP2359861A1 (en) Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
EA034565B1 (ru) Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии
JP5103476B2 (ja) シクロデキストリン・ドセタキセルの包接体を含む薬物組成物及びその製造方法
KR101739816B1 (ko) 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
CN100486645C (zh) 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100479807C (zh) 药物输送系统——固体纳米药物的制备方法
Vadlamudi et al. Disparate practical way of doing solubility enhancement study to improve the bioavailability of poorly soluble drugs
CN100508969C (zh) 紫杉烷环糊精包合物纳米粒及其制备方法
Sanklecha A systematic review on solid dispersion: Enhancing the solubility of poorly soluble drug
Bhargav Beta-Cyclodextrin As An Excipient In Drug Formulation
Jain et al. Solubility enhancement techniques for natural product delivery
Bajait et al. Importance of solubility and solubility enhancement techniques
WO2004089338A1 (en) A arbidol clathrate and its preparation process and the use thereof
Alhayyan et al. Techniques for Improving Solubility
Shyamala et al. Cyclodextrin in Formulation Development: A Review
Jain et al. Solid Dispersion Technique: A Strategic Solution to Boost Solubility

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330